Ranitidine
(E)-1-N'-[2-[[5-[(Dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine
Drag to rotate. Structure from PubChem CID 3001055.
Background
Listing
- Schedules
- Schedule 2 to 3, conditions apply
- Source
- Consolidated Schedules 06 July 2026
Registered medicines
1 registered product listed
Counted through the register's ingredient index, which does not reach every record.
| Name | Brands | Dosages | Applicants | Registrations | Schedule |
|---|---|---|---|---|---|
| Ranitidine | Ebunazi, Rantac, Ebunaziinjection, +24 more | 150 mg, 300 mg, injection, 50 mg/2 ml, +1 more | 16 applicants | 54 registrations | S2 to S3conditions apply |
Regulatory status
Where S2 to S3 sits on the scale
Depends on which listing applies
At the least restrictive, Schedule 2: a pharmacist can sell it directly, without a prescription. At the most restrictive, Schedule 3: needs a doctor's prescription, dispensed by a pharmacist. The listings below say which applies to which form, strength or pack size.
Schedule S2 to S3, as the Consolidated Schedules list it.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Ranitidine
S3: Ranitidine
- except where administered orally for short-term symptomatic relief of heartburn and hyperacidity, subject to a maximum dose of 75 milligrams, a maximum daily dose of 300 milligrams and a maximum treatment period of two weeks. (S2)
Consolidated Schedules 06 July 2026, lines 4205 to 4207
S2: Ranitidine
- when administered orally for short-term symptomatic relief of heartburn and hyperacidity, subject to -
- when a maximum dose of 75 milligrams;
- when a maximum daily dose of 300 milligrams;
- when a maximum treatment period of two weeks. (S3)
Consolidated Schedules 06 July 2026, lines 2625 to 2632
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.